ASO
(Antisense Oligonucleotides)

Antisense nucleic acid treatment technology is a third-generation drug development technology using oligo nucleic acids such as DNA/RNA/PNA. It effectively suppresses the expression of disease genes by specifically inhibiting the production of disease-causing proteins through acting on mRNA, which is the pre-stage of protein production. Therefore, it is a next-generation drug development technology that enables the development of new medicines for targets that were impossible to develop.

PNA
(Peptide Nucleic Acids)

PNA is polymeric compound in which the sugar-phosphate backbone of DNA is replaced with a peptide backbone.
Unlike DNA/RNA, it has excellent in vivo stability and has very high binding affinity with target genes.

​​​​​​​

​​​​​​​

PNA is electrically neutral, unlike negatively charged DNA/RNA, so it is difficult to transfer into cells and self-aggregation occurs.

POLIGO^{TM
(PNA Oligonucleotide technology)}